Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

September 8, 2026 7:30 AM EDT Send to a Friend
Needham analyst Chad Messer reiterated a Buy rating and $86.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "Novartis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login